Key Points on ACRV Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
*Acrivon has a consensus analyst rating of Moderate Buy from seven analysts (1 sell, 1 hold, 4 buy, 1 strong buy) and an average 1-year price target of $11.00.
*Shares opened at $2.46 with a market cap of $77.64 million and a 52-week range of $1.05–$8.00; analysts expect about -2.49 EPS for the year after the company reported a quarterly loss of ($0.47) that beat estimates.
*Acrivon is a clinical-stage biotech developing hydrocarbon-stapled peptide therapeutics for RAS-driven cancers, including a KRAS G12C candidate currently in early clinical trials.
*MarketBeat previews the top five stocks to own by February 1st.
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has received a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.00.